Ortho-McNeil To Acquire U.S. Rights To AXERT
Ortho-McNeil Pharmaceutical, Inc. is to acquire the U.S. sales and marketing rights to AXERT (almotriptan malate) Tablets, pursuant to a licensing agreement with the drug’s innovator Almirall. AXERT is a prescription medication approved to treat migraine headaches in adults. Completion of the transaction, which is expected to occur during the second quarter of 2003, is Read more about Ortho-McNeil To Acquire U.S. Rights To AXERT[…]